Viridian Therapeutics, Inc.

This phase 3 trial tests an investigational drug called VRDN-003, given as an injection under the skin, for people with thyroid eye disease. The study involves 320 participants and aims to check the drug's safety and tolerability. Researchers will also measure if it reduces eye b…

This phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …

This Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…